Patent Application
20240011020
In nucleic acid assays, the presence of a target nucleic acid sequence can be used for determining the presence or absence of a particular genetic sequence or organisms. Numerous methods exist for identifying the presence of the target nucleic acid sequence. These methods often involve the selective amplification of the target nucleic acid to a quantity above a threshold that then allows the target nucleic acid to be detected. One possible method would be to amplify the target nucleic acid via polymerase chain reaction and then identifying the target via sequencing. However, there are challenges to increasing the multiplexity of such a method to allow simultaneous detection of the target nucleic acid in many samples. Provided herein are compositions and methods for addressing this problem.
In general, the present invention relates to oligonucleotides employed in the amplification and barcoding of a target nucleic acid sequence from a nucleic acid sample and methods of use thereof.
In one aspect, the invention provides a pair of sequencing oligonucleotides. The first sequencing oligonucleotide includes, from 5′ to 3′, a first barcode primer region, a first sequencing primer region, a first in-line barcode region, and a first target-specific binding region complementary to a first sequence in a target nucleic acid. The second sequencing oligonucleotide includes, from 5′ to 3′, a second barcode primer region and a second target-specific binding region homologous to a second sequence in the target nucleic acid. The first and second sequences flank a sequencing assay region in the target nucleic acid that can be amplified using the pair.
In some embodiments, the second oligonucleotide further includes a second sequencing primer region between the second barcode primer region and the second target-specific binding region.
In some embodiments, the second oligonucleotide further includes a second in-line barcode region between the second barcode primer region and the second target-specific binding region.
In some embodiments, the sequencing oligonucleotides may include RNA, DNA, or a combination thereof.
In another aspect, the invention provides a kit that includes a pair of sequencing oligonucleotides described herein, as well as a pair of barcoding oligonucleotides. The first barcoding oligonucleotide includes, from 5′ to 3′, a first region for attachment to a solid substrate, a first unique barcode sequence, and a first primer region homologous to the first barcode primer region. The second barcoding oligonucleotide includes, from 5′ to 3′, a second region for attachment to a solid substrate, a second unique barcode sequence, and a second primer region homologous to the second barcode primer region.
In some embodiments, the kit further includes a plurality of pairs of sequencing oligonucleotides, where the sequence of the first in-line barcode region for each first oligonucleotide is different.
In some embodiments the kit further includes a plurality of pairs of barcoding oligonucleotides, where the sequence of the first unique barcode sequence for each first barcoding oligonucleotide is different.
In some embodiments, the kit further includes a plurality of pairs of barcoding oligonucleotides, where the sequence of the second unique barcode sequence for each second barcoding oligonucleotide is different.
In another aspect, the invention provides a method of generating a library from a nucleic acid sample by using a kit described herein to amplify the nucleic acid sample and produce amplicons. The amplicons are nucleic acids that include the first region for attachment to a solid substrate, the first unique barcode sequence, the first barcode primer region, the first sequencing primer region, the first in-line barcode region, the first target-specific binding region, the sequencing assay region, the complement sequence of the second target-specific binding region, the complement sequence of the second barcode primer region, the complement sequence of the second unique barcode sequence, and the complement sequence of the second region for attachment to a solid substrate, and its complementary strand.
In certain embodiments, the method amplifies the nucleic acid sample to produce the library in a single step using the pair of sequencing oligonucleotides and the pair of barcoding oligonucleotides in the same reaction mixture.
In other embodiments, the method amplifies the nucleic acid sample to produce the library in two steps. The first step uses the pair of sequencing oligonucleotides to produce an intermediate amplicon, which is a nucleic acid that includes the first barcode primer region, the first sequencing primer region, the first in-line barcode region, the first target-specific binding region, the sequencing assay region, the complement sequence of the second target-specific binding region, and the complement sequence of the second barcode primer region and its complementary strand. The second step amplifies the intermediate amplicon using the pair of barcoding oligonucleotides to produce the amplicons of the library.
In another aspect, the invention provides a method of sequencing a target nucleic acid sequence in a nucleic acid sample. Provided the amplicons described herein, at least a portion of the amplicons are hybridized to a solid substrate, from which a covalently bound complementary strand is created. The covalently bound complementary strand is then sequenced, which includes sequencing the first in-line barcode region, the first target specific binding region, and the sequencing assay region through sequencing-by-synthesis using a sequencing primer homologous to the first sequencing primer region. The first and second unique barcode sequences of the amplicon are also sequenced.
In some embodiments, the amplicons are hybridized via their first and/or second region for attachment to a solid substrate to immobilized primers covalently attached to the solid substrate.
In some embodiments, the immobilized primer covalently attached to the solid surface is used to generate a complement of the hybridized amplicon through polymerase extension.
In certain embodiments, the first and second unique barcode sequences are sequenced by index reads.
In other embodiments, the first unique barcode is sequenced by index read, and the second unique barcode is sequenced by extending the sequence-by-synthesis step up to the complement sequence of the second unique barcode sequence.
The following definitions are provided for specific terms, which are used in the disclosure of the present invention:
By “amplify” or “amplification” is meant a method to create copies of a nucleic acid molecule. In some instances, the amplification may be achieved using polymerase chain reaction (PCR) or ligase chain reaction (LCR). In other instances, the amplification may be achieved using more than one round of polymerase chain reaction, e.g., two rounds of polymerase chain reaction. In some instances, PCR may be performed using one or more pairs of sequencing oligonucleotides and/or one or more pairs of barcoding oligonucleotides as primers.
By “barcode” is meant a unique oligonucleotide sequence that may allow the corresponding oligonucleotide to be identified. In some embodiments, the nucleic acid sequence may be located at a specific position in a longer nucleic acid sequence. In some embodiments, each barcode may be different from every other barcode by at least a minimum Hamming Distance, wherein the minimum Hamming Distance may be a number greater or equal to 2.
By “complement” or “complementary” sequence is meant the sequence of a first nucleic acid in relation to that of a second nucleic acid, wherein when the first and second nucleic acids are aligned antiparallel (5′ end of the first nucleic acid matched to the 3′ end of the second nucleic acid, and vice versa) to each other, the nucleotide bases at each position in their sequences will have complementary structures following a lock-and-key principle (i.e., A will be paired with U or T and G will be paired with C). Complementary sequences may include mismatches of up to one third of nucleotide bases. For example, two sequences that are nine bases in length may have mismatches of at most 3, at most 2, or at most 1, or at most 0 nucleotide bases, and remain complementary to one another.
By “flank” is meant the relative positions of three nucleic acid regions. A first and second nucleic acid region is said to flank a third nucleic acid region if the first and second regions lie immediately upstream and downstream of the third nucleic acid region.
By “Hamming Distance” is meant a relationship between two nucleic acid sequences of equal length, wherein the number corresponding to the Hamming Distance is the number of bases by which two sequences of equal lengths differ.
By “homologous” is meant having substantially the same sequence. Homologous sequences may differ by up to one third of nucleotide bases. For example, two sequences that are nine bases in length may differ at most by 3, at most by 2, at most by 1, or at most by 0 nucleotide bases, and remain homologous to one another.
By “hybridization” is meant a process in which two single-stranded nucleic acids bind non-covalently by base pairing to form a stable double-stranded nucleic acid. Hybridization may occur for the entire lengths of the two nucleic acids, or only for a portion or subregion of one or both of the nucleic acids. The resulting double-stranded nucleic acid molecule or region is a “duplex.”
By “index read” is meant a method of sequencing a nucleic acid sequence, including a known unique barcode sequence, wherein a sequencing primer is hybridized upstream of the unique barcode sequence, and the nucleic acid read via sequencing-by-synthesis. Index read does not refer to sequencing of the target nucleic acid.
By “library” is meant the amplification product of multiple nucleic acids, wherein the multiple nucleic acids may have the same or different sequences.
By “nucleic acid” is meant a polymeric molecule of at least two linked nucleotides. The terms include, for example, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), as well as hybrids and mixtures thereof. A nucleic acid may be single-stranded, double-stranded, or contain a mix of regions or portions of both single-stranded or double-stranded sequences. The nucleotides in a nucleic acid are usually linked by phosphodiester bonds, though “nucleic acid” may also refer to other molecular analogs having other types of chemical bonds or backbones, including, but not limited to, phosphoramide, phosphorothioate, phosphorodithioate, O-methyl phosphoramidate, morpholino, locked nucleic acid (LNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), and peptide nucleic acid (PNA) linkages or backbones. Nucleic acids may contain any combination of deoxyribonucleotides, ribonucleotides, or non-natural analogs thereof. Examples of nucleic acids include, but are not limited to, a gene, a gene fragment, a genomic gap, an exon, an intron, intergenic DNA (including, without limitation, heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, small interfering RNA (siRNA), miRNA, small nucleolar RNA (snoRNA), cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of a sequence, isolated RNA of a sequence, nucleic acid probes, and primers.
By “nucleotide” is meant any deoxyribonucleotide, ribonucleotide, non-standard nucleotide, modified nucleotide, or nucleotide analog. Nucleotides include adenine, thymine, cytosine, guanine, and uracil. Examples of modified nucleotides include, but are not limited to, diaminopurine, 5-fluorouracil, 5-bromouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5-methoxyuracil, 2-methylthio-D46-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil.
By “oligonucleotide” is meant a nucleic acid up to 150 nucleotides in length. Oligonucleotides may be synthetic. Oligonucleotides may contain one or more chemical modifications, whether on the 5′ end, the 3′ end, or internally. Examples of chemical modifications include, but are not limited to, addition of functional groups (e.g., biotins, amino modifiers, alkynes, thiol modifiers, or azides), fluorophores (e.g. quantum dots or organic dyes), spacers (e.g. C3 spacer, dSpacer, photo-cleavable spacers), modified bases, or modified backbones.
By “sequencing-by-ligation” is meant a method of sequencing a nucleic acid, wherein multiple cycles of ligation sequencing are performed. In each cycle of ligation sequencing, a ligation primer is first hybridized immediately upstream of the region of a target nucleic acid to be sequenced, and multiple rounds of ligation are performed. In each round of ligation, a pool of short oligonucleotides (typically containing 8 or 9 nucleotides but can be shorter or longer) is presented to the nucleic acid being sequenced, and the best matching complementary sequence will be ligated. The identity of one or more nucleotides on the short oligonucleotides is typically encoded via a fluorophore, wherein imaging following each round of ligation can determine the identity of the bases on the nucleic acid being sequenced in the corresponding positions. Multiple rounds of ligation are performed until the end of the nucleic acid being sequenced. The ligated strand can then be removed, and a new ligation primer one or more bases away from the previous ligation primer can be used to begin a new cycle of ligation sequencing. Multiple cycles of ligation sequencing are performed until the identity of the entire nucleic acid being sequenced has been determined.
By “sequencing-by-synthesis” is meant a method of sequencing a nucleic acid, wherein a sequencing primer is first hybridized immediately upstream of the region of a target nucleic acid to be sequenced, and multiple rounds of sequencing cycles are performed. During each sequencing cycle, a single, complementary, detectable, e.g., fluorescently labeled, nucleotide is added to the nucleic acid downstream of the extending sequencing primer. The sequence of the target nucleic acid is then determined based upon the fluorescent signals observed during each sequencing cycle. It will be understood that the sequence of a sequencing assay region can be determined by sequencing the sense or antisense strand or both.
By “sequence in-line” is meant a method of sequencing a nucleic acid sequence, wherein the nucleic acid sequence is sequenced by extending a sequencing-by-synthesis reaction to include one or more nucleic acid sequences that lie downstream of the same strand of nucleic acid undergoing sequencing-by-synthesis.
By “target nucleic acid” is meant any nucleic acid (e.g., RNA or DNA) of interest that is selected for amplification or analysis (e.g., sequencing) using a composition (e.g., sequencing oligonucleotides or barcoding oligonucleotides) or method of the invention. In some instances, RNA may be converted to cDNA prior to being treated with a composition of the invention (e.g., sequencing oligonucleotides or barcoding oligonucleotides).
We have developed new oligonucleotides and methods of their use that increase the number of samples that can be sequenced in parallel. Disclosed herein are compositions, kits, and methods for amplifying a sequencing assay region of a target nucleic acid from a nucleic acid sample from any source, while simultaneously adding a plurality of barcode sequences during the amplification process, to create a library of amplified amplicons which is then sequenced, with the barcode sequences enabling identification of the nucleic acid sample from which the amplicon derives. The compositions and methods herein can be used in a variety of applications, particularly those identifying the sequence of a target nucleic acid from nucleic acid samples in a highly multiplexed manner. The inventive approach combines the high specificity and sensitivity of qPCR assays with the high detection resolution and throughput offered by next-generation sequencing (NGS) methods by leveraging PCR amplification to encode NGS reads with additional barcoding regions in a combinatorial manner. The compositions and methods can be used, for example, to create amplicons containing combinatorial barcodes for the purposes of rapidly sequencing many nucleic acid samples for the presence of viral or mutant nucleic acids.
NGS is a powerful tool in molecular biology. The technology involves millions of nucleic acid strands being read in parallel, one base at a time. Depending on the method used, the DNA strand is read from one or both ends of the DNA molecule. To leverage the growing raw sequencing output of NextGen Sequencing platforms for more samples, barcode sequences (indexes) were incorporated by manufacturers into the synthetic adapters used for NGS library construction. Later during data analysis, the barcode sequences were used to assign sequencing reads to specific samples. Using conventional library preparation methods, barcode sequences could either be encoded in the adapter at one end (single-index sequencing) or in the adapters at both ends (dual-index sequencing).
Over the past decade, DNA sequencing systems have evolved from a throughput of several megabases per day to a throughput of terabases per day, including the use of patterned flow cells that provide known locations and dimensions. This increase in throughput has provided the capacity to simultaneously sequence DNA from multiple sources of nucleic acids using multiplexed libraries. Despite the improvements to throughput, however, the scientific community has reported instances of the misassignment of reads in multiplex libraries, coming from a switch to a new exclusion amplification (ExAmp) technology.
Unique dual index (UDI) sequencing is the current industry standard for DNA sequencing because UDIs address the challenges of crosstalk and read contamination between samples, which lead to sample misassignment. When preparing samples for sequencing on the Illumina® sequencing systems, unique dual indexes (i5 and i7 barcodes) are added to the 5′ and 3′ ends of NGS library fragments during library amplification with primers carrying unique pairs of barcodes or by ligation of adapters carrying unique pairs of barcodes.
The advantage of labeling samples using UDIs is realized when libraries derived from separate samples are sequenced together on the same run and analyzed. Reads carrying the expected barcode combination can be distinguished from reads carrying unexpected barcode combinations arising from cross-contamination of reagents, misincorporation of barcode sequences during amplification on the sequencing system, or optical crosstalk during data acquisition. Reads carrying the expected barcode combinations are computationally assigned to each corresponding sample, while reads carrying unexpected barcode combinations are discarded (i.e., are not used for analysis).
Modern NGS systems typically generate millions of paired reads per sequencing run. For example, Illumina sequencing systems generate as few as 1 million paired reads per run for small desktop sequencers such as the MiSeq™ System, and up to 10 billion paired reads per run for large production scale sequencers such as the NovaSeg™ 6000 System.
Small nucleic acid targets, such as 300 bp amplicons, rarely require a depth of sequencing greater than 100× to confidently determine the DNA sequence. If 100× was set as the minimum threshold for coverage, a paired read configuration of 2×151 bases could be applied to sequence a 300 bp amplicon. If amplicons were then prepared from 384 samples and UDIs were added to uniquely label library fragments from each sample, those 384 samples could be analyzed in a single NovaSeq™ 6000 sequencing run. If 10 billion read pairs were obtained, the average number of UDI read pairs per sample would be approximately 26 million (10 billion read pairs/384 samples). In this example, 26 million read pairs would be an extremely unproductive use of sequencing output because the minimum threshold for sequencing depth is 100×, i.e., only requiring 100 read pairs per sample. This example illustrates that many more samples could be sequenced per run if more than 384 UDIs were readily available. However, most commercially available UDIs are available as a maximum of 384 pairs of UDIs. The number of UDIs needed to scale-up the number of samples per sequencing run increases in a linear fashion. Currently, to achieve higher levels of multiplexing with UDIs, larger sets of UDI-primers or UDI-adapters would need to be validated, manufactured, and quality-controlled before use.
The compositions of the invention include a pair of sequencing oligonucleotides that allow the insertion of an in-line barcode in the resulting nucleic acid product of an amplification reaction. The sequencing oligonucleotides may be employed with a pair of barcoding oligonucleotides that allow the insertion of an additional pair of unique barcode sequences, e.g., UDIs, to the nucleic acid product of the amplification reaction.
The invention provides compositions that include a pair of sequencing oligonucleotides. As depicted in
Each region of the sequencing oligonucleotide may include 5-30 nucleotides. For example, the barcode primer regions may include 7-20 nt; the sequencing primer regions may include 12-30 nt; the in-line barcode regions may include 5-18 nt; and the target-specific binding region may include 5-30 nt. The overall sequence of the oligonucleotides is chosen to be non-naturally occurring. In certain embodiments, the in-line barcode regions are immediately 3′ of the barcode primer region, allowing for determination of the in-line barcode sequence first. In some embodiments, the sequencing oligonucleotides may include RNA, DNA, or a combination thereof. The sequencing oligonucleotides may also contain modified nucleotides, e.g., modified bases, sugars, or phosphates. In one embodiment, uracil is substituted for positions where thymine appears in the sequencing oligonucleotides, which allows removal of trace amounts of synthetic oligonucleotide and carryover PCR products by pretreatment with uracil-DNA glycosylase (UDG).
The first and second target-specific binding regions flank a sequencing assay region in the target nucleic acid and allow for amplification thereof. As depicted in
In certain embodiments, the pair of sequencing oligonucleotides may not contain a first or second target-specific binding region. Instead, the first sequencing oligonucleotide would include, from 5′ to 3′, a first barcode primer region, a first sequencing primer region, and a first in-line barcode region. The second sequencing oligonucleotide could either include only a complementary sequence of a second barcode primer region; from 5′ to 3′, a complementary sequence of a second barcode primer region and a complementary sequence of a second sequencing primer region; or, from 5′ to 3′, a complementary sequence of a second barcode primer region, a complementary sequence of a second sequencing primer region, and a complementary sequence of a second in-line barcode region. In other embodiments, the first sequencing oligonucleotide would include, from 5′ to 3′, a complementary sequence of a first barcode primer region, a complementary sequence of a first sequencing primer region, and a complementary sequence of a first in-line barcode region. The second sequencing oligonucleotide could either include only a second barcode primer region; from 5′ to 3′, a second barcode primer region and a second sequencing primer region; or, from 5′ to 3′, a second barcode primer region, a second sequencing primer region, and a second in-line barcode region. In some embodiments, the sequencing oligonucleotides may include RNA, DNA, or a combination thereof.
The invention further provides compositions that include a pair of barcoding oligonucleotides. As depicted in
Each region of the barcoding oligonucleotide may include 5-20 nucleotides. For example, the unique barcode sequences may have 5-18 nt and the primer regions may have 7-20 nt. The regions for attachment to a solid substrate, e.g., P5 and/or P7, may have 12-30 nt. The overall sequence of the oligonucleotides is chosen to be non-naturally occurring. In certain embodiments, the unique barcode sequences are a UDI pair. In some embodiments, the barcoding oligonucleotides may include RNA, DNA, or a combination thereof. The barcoding oligonucleotides may also contain modified nucleotides, e.g., modified bases, sugars, or phosphates. In one embodiment, uracil is substituted for positions where thymine appears in the barcoding oligonucleotides, which allows removal of trace amounts of synthetic oligonucleotide and carryover PCR products by pretreatment with uracil-DNA glycosylase (UDG).
As further depicted in
The invention provides kits and other combinations of the oligonucleotides. For example, a kit may include a plurality of pairs of sequencing oligonucleotides, where each pair of sequencing oligonucleotides may have different in-line barcodes and optionally are otherwise the same. For example, a kit may include 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24, 32, 64, 96, 100, 128, 150, 200, 250, 256, 300, 350, 384, 400, 500, 512, 600, 700, 800, 900, 1000, or more pairs of sequencing oligonucleotides with different in-line barcode regions. A kit may also include a plurality of pairs of barcoding oligonucleotides, where the sequence of the first unique barcode sequence for each first barcoding oligonucleotide is different and optionally the remaining sequences are identical. For example, a kit may include 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 18, 20, 22, 24, 32, 64, 96, 100, 128, 150, 200, 250, 256, 300, 350, 384, 400, 500, 512, 600, 700, 800, 900, 1000, or more first barcoding oligonucleotides, where the first unique barcode sequences are different. In some embodiments, the pairs of barcoding oligonucleotides include a second unique barcode sequence, where each second barcoding oligonucleotide is different. For example, a kit may include 2, 3, 4, 5, 6, 7, 8, 12, 14, 16, 18, 20, 22, 24, 32, 64, 96, 100, 128, 150, 200, 250, 256, 300, 350, 384, 400, 500, 512, 600, 700, 800, 900, 1000, or more second barcoding oligonucleotides, where the second unique barcode sequences are different and optionally the remaining sequences are identical. Two different pairs of barcoding oligonucleotides are considered different whether they differ by only their first barcoding oligonucleotides, by only their second barcoding oligonucleotides, or by both their first and second barcoding oligonucleotides.
For a given amplification reaction, the barcode primer regions of the sequencing oligonucleotides and the primer regions of the barcoding oligonucleotides are homologous. In certain embodiments, the sequences are identical. In certain embodiments, the only regions of barcoding oligonucleotides fully complementary to the amplification product of the sequencing oligonucleotides are the primer regions.
The invention features methods to generate amplicons using the oligonucleotide pairs of the invention as primers in one or more nucleic acid amplification reactions (e.g., PCR or RT-PCR), wherein the generated amplicons include a target nucleic acid sequence, an in-line barcode sequence and a pair of unique barcode sequences. The invention also features methods to sequence the generated amplicons described herein, wherein the sequences of the target nucleic acid sequence, in-line barcode sequence, and unique barcode sequences are determined to associate the target nucleic acid to a nucleic acid sample corresponding to the in-line barcode sequence and unique barcode sequences.
The invention further provides a method for the generation of a nucleic acid library of amplicons. As depicted in
In certain embodiments, the one or more pairs of sequencing oligonucleotides and one or more pairs of barcoding oligonucleotides may be added simultaneously as primers in a single nucleic acid amplification reaction. In other embodiments, the pairs of sequencing oligonucleotides are first added as primers in a first amplification reaction, where, as depicted in
In yet other embodiments, the pair of sequencing oligonucleotides may not contain a first and second target-specific binding region. Instead, the method would include two steps. In the first step, the in-line barcode region(s) may be added to the target nucleic acid via ligation of a pair of sequencing oligonucleotides that do not contain a first and second target-specific binding regions to produce intermediate amplicons. In the second step, the intermediate amplicons may be amplified using the pair of barcoding oligonucleotides, as described herein.
Nucleic acid amplification reactions described herein may involve at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, or more cycles of amplification.
The invention further provides a method for the sequencing of a nucleic acid library of amplicons. As depicted in
In some embodiments, the amplicons and their complement sequences are hybridized via their first or second regions for attachment to a solid substrate to a complementary primer region covalently bound to a solid surface (
In certain embodiments, as depicted in
In some embodiments, sequencing-by-ligation may be used to determine the sequences of the sequencing assay region, the first and second in-line barcode regions, and/or the first and second unique barcode sequences.
The sequencing may, for example, be performed on an NGS platform, though other methods of nucleic acid sequencing may be used. At least 1, 5, 10, 15, 20, 30, 40, 50, 75, 100, 200, 300, 400, 500, 1000, 2000, 3000, 5000, 7500, 10000, 50000, 100000, 500000, 750000 or more amplicons can be sequenced simultaneously. At least 1 million, 2 million, 3 million, 5 million, 10 million, 20 million, 30 million, million, 100 million, 200 million, 300 million, 500 million, 750 million, 1 billion, 2 billion, 3 billion, 4 billion, 5 billion, 6 billion, 7 billion, 8 billion, 9 billion, 10 billion, 11 billion, 12, billion, 13 billion, 14 billion, 15 billion, or more amplicons may be sequenced simultaneously.
The invention will now be described by the following non-limiting examples.
Two-step amplicon library preparation procedure:
Heat-inactivated SARS-CoV-2 (ATCC)
TaqPath Master Mix (Thermo)
Pairs of sequencing oligonucleotides:
Pairs of barcoding oligonucleotides (Illumina; UD Indexes Plate B/Set2: UDP0169-UDP0192)
MAGwise paramagnetic beads (seqWell)
6. Transferred the capped 8-strip PCR tubes containing the reactions to a thermal cycler and ran the following barcode amplification thermal cycling program:
Barcode amplification program (10 cycles):
After demultiplexing the sequencing results from the MiSeq run, the number of reads with exact matches to the first 9 bases, corresponding to the in-line barcode region and the 50 bases of the N1, N2 and RP amplicons were counted (see below) for each sample:
The results for Example 1 are shown in
The number of barcode combinations can be increased by using sequencing oligonucleotides with in-line barcode regions in conjunction with a set of barcoding oligonucleotides. A set of 384 barcoding oligonucleotides combinations can be expanded to 768 barcode combinations by only adding two pairs of oligonucleotides which include three new oligonucleotide sequences: two first sequencing oligonucleotides with different in-line barcode sequences and a second sequencing oligonucleotide. See the chart in
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2021/049422 | 9/8/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63075682 | Sep 2020 | US |
